Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00584298 | Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide | PHASE1 | COMPLETED | 50 | — | — | Jan 1, 2008 | - | May 8, 2009 | 7 | United States, Canada +2 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SMS995 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * A positive diagnosis of IBS. * Subjects must either have been surgically sterilized, hysterectomized at least 6 months prior to screening, be postmenopausal or be using a double-barrier local * contraception. * Able to communicate well with the investigator, to understand and ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Ardelyx, Inc. | ARDX | 4 | PHASE3 | Tenapanor |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | — | Undisclosed |
| Johnson & Johnson | JNJ | 1 | — | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | NA | Undisclosed |